Transcript of Business Update Call with Investors and Analysts
AI summary
- Announced INR 500 Cr investment in three strategic growth initiatives
- Ibuprofen capacity expansion by 6,000 MTPA to 18,000 MTPA, commissioning by Dec 2027
- New CDMO facility with 1,500 mn tablets capacity, EU GMP certified, commercializing Q3 FY27
- Specialty chemical facility under tolling arrangement with global customer
- Initiatives expected to add 25-30% incremental top line by FY29
- Capex funded fully from internal accruals; 30% already spent
- Ibuprofen asset turns ~1.75x; optimal utilization >80% by FY29
- CDMO margins expected better than API; optimal utilization in 18-24 months
- Ibuprofen prices stable; backward integration controls raw material cost
- ROCE from projects expected ~15% at steady state
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 IOLCP — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add IOLCP to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on IOL Chemicals and Pharmaceuticals Limited
Important.
The summary above is generated automatically from IOL Chemicals and Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.